JP2005536543A - ビオチンを含む新規栄養補助食品組成物 - Google Patents
ビオチンを含む新規栄養補助食品組成物 Download PDFInfo
- Publication number
- JP2005536543A JP2005536543A JP2004530180A JP2004530180A JP2005536543A JP 2005536543 A JP2005536543 A JP 2005536543A JP 2004530180 A JP2004530180 A JP 2004530180A JP 2004530180 A JP2004530180 A JP 2004530180A JP 2005536543 A JP2005536543 A JP 2005536543A
- Authority
- JP
- Japan
- Prior art keywords
- biotin
- diabetes
- composition
- egcg
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims description 172
- 235000020958 biotin Nutrition 0.000 title claims description 86
- 239000011616 biotin Substances 0.000 title claims description 86
- 229960002685 biotin Drugs 0.000 title claims description 86
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 claims abstract description 66
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 claims abstract description 64
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 55
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 55
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims abstract description 48
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims abstract description 46
- 235000008975 pantethine Nutrition 0.000 claims abstract description 46
- 229960000903 pantethine Drugs 0.000 claims abstract description 46
- 239000011581 pantethine Substances 0.000 claims abstract description 46
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 44
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 44
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 44
- 229960001109 policosanol Drugs 0.000 claims abstract description 34
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 34
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 230000037396 body weight Effects 0.000 claims abstract description 24
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 20
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 17
- 239000002207 metabolite Substances 0.000 claims abstract description 15
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 208000001280 Prediabetic State Diseases 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 23
- 235000013361 beverage Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 6
- 239000013589 supplement Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 49
- 239000008103 glucose Substances 0.000 description 49
- 229940030275 epigallocatechin gallate Drugs 0.000 description 44
- 206010012601 diabetes mellitus Diseases 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 9
- 201000001421 hyperglycemia Diseases 0.000 description 9
- 229960003151 mercaptamine Drugs 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 7
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 239000002417 nutraceutical Substances 0.000 description 7
- 235000021436 nutraceutical agent Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000004190 glucose uptake Effects 0.000 description 5
- 230000002641 glycemic effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010021582 Glucokinase Proteins 0.000 description 4
- 102000030595 Glucokinase Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 101710097943 Viral-enhancing factor Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 238000010304 firing Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 3
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 235000020772 multivitamin supplement Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000014594 pastries Nutrition 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- ULCZGKYHRYJXAU-UHFFFAOYSA-N heptacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCO ULCZGKYHRYJXAU-UHFFFAOYSA-N 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 235000021579 juice concentrates Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- JCTHECMTHPMGHF-UHFFFAOYSA-N C1CSSC1.CC=CCC(O)=O Chemical compound C1CSSC1.CC=CCC(O)=O JCTHECMTHPMGHF-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012165 plant wax Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/36—Vegetable material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/366—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
ビオチン及びフィタン酸;
ビオチン及びEGCG;
ビオチン及びリポ酸;
ビオチン、フィタン酸及びEGCG;
ビオチン、フィタン酸及びパンテチン;
ビオチン、パンテチン及びEGCG;並びに
ビオチン、フィタン酸、パンテチン及びEGCG。
ビオチン:0.7〜210mg/日
EGCG:20〜2100mg/日
パンテチン:70〜3500mg/日
フィタン酸:70〜7000mg/日
リポ酸:20〜2100mg/日
ポリコサノール:0.15〜100mg/日
軟ゼラチンカプセル剤は、下記の成分を使用して、従来の手順により調製した。
活性成分:ビオチン30mg パンテチン100mg
その他の成分:グリセロール、水、ゼラチン、植物油
硬ゼラチンカプセル剤は、下記の成分を使用して、従来の手順により調製した。
活性成分:ビオチン30mg パンテチン100mg
その他の成分:
増量剤:乳糖又はセルロースもしくはセルロース誘導体 十分量
滑沢剤:必要であれば、ステアリン酸マグネシウム(0.5%)
錠剤は、下記の成分を使用して、従来の手順により調製した。
活性成分:ビオチン20mg、パンテチン50mg
その他の成分:微晶質セルロース、二酸化シリコン(SiO2)、ステアリン酸マグネシウム、クロスカルメロースナトリウム
活性成分:
ビオチン、並びに場合により、パンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:240ml
ジュース濃縮物及び水溶性香料
[g]
オレンジ濃縮物 60.3°Brix、5.15%酸性度 657.99
レモン濃縮物 43.5°Brix、32.7%酸性度 95.96
オレンジ香料、水溶性 13.43
アンズ香料、水溶性 6.71
水 26.46
β−カロテン10%CWS 0.89
水 67.65
アスコルビン酸 4.11
無水クエン酸 0.69
水 43.18
ペクチン 0.20
安息香酸ナトリウム 2.74
水 65.60
オレンジ香料、油溶性 0.34
オレンジ油 蒸留物 0.34
前記の濃度の活性成分(これは、前記の活性成分:ビオチン、並びにEGCG、パンテチン、リポ酸及び/又はフィタン酸のうちの一つ以上を意味する)。
[g]
ソフトドリンク化合物 74.50
水 50.00
糖シロップ 60°Brix 150.00
安息香酸ナトリウムを使用する代わりに、飲料を低温殺菌してもよい。飲料は、炭化されてもよい。
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:50g
[%]
五穀粉 56.8
水 39.8
イースト 2.3
塩 1.1
混捏:
螺旋型混捏システム 4分 第1ギア;5分 第2ギア
生地膨化(proofing):60分
生地温度:22〜24℃
膨化時間:30分
焼成:
オーブン:ダッチタイプオーブン
焼成温度:250/220℃
焼成時間:50〜60分
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:30g
[g]
小麦粉、タイプ550 41.0
砂糖 20.5
脂肪/バター 20.5
全卵(液状) 18.0
レモン香料 十分量
ベーキング剤 十分量
オーブン:ファンオーブン
焼成温度:180℃
焼成時間:15分
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:100g
[%]
小麦粉 タイプ550 55.4
水 33.2
イースト 2.8
塩 1.1
脂肪/バター 5.5
麦芽 0.6
乳化ベーキング剤 1.4
混捏:
螺旋型混捏システム 5〜6分 第1ギア;3〜4分 第2ギア
生地膨化:なし
生地温度:22〜24℃
膨化時間:40分
焼成:
オーブン:ダッチタイプオーブン
焼成温度:220℃
焼成時間:35〜40分
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:225g
[%]
全脂肪乳(脂肪分3.8%) 90.5
脱脂粉乳 2.0
砂糖 5.0
培養物 2.5
ビオチン、並びに場合によりパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:225g
[%]
全脂肪乳(脂肪分3.8%) 90.2
脱脂粉乳 2.0
安定剤 0.3
砂糖 5.0
培養物 2.5
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:85g
[%]
牛乳(脂肪分3.7%) 600.00
乳脂(脂肪分35%) 166.00
脱脂粉乳 49.10
砂糖 109.00
ブドウ糖シロップ80% 70.00
アイスクリーム安定剤 5.00
香料 十分量
着色料 十分量
活性成分:
ビオチン、並びにパンテチン、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される一つ以上の付加的な成分を、この食品アイテムに配合した。
ビオチン:一食分当たり0.03〜50mg
パンテチン:一食分当たり20〜800mg
EGCG:一食分当たり5〜500mg
フィタン酸:一食分当たり20〜2000mg
リポ酸:一食分当たり5〜500mg
ポリコサノール:一食分当たり0.1〜20mg
典型的な一食分:30g
[g]
ゼラチン200ブルーム 80.0
水I 125.0
砂糖結晶 290.0
水II 120.0
ブドウ糖シロップDE38 390.0
クエン酸 10.0
香料 2.0
着色料 十分量
全量 およそ1000.0
ビオチン及びフィタン酸の組み合わせ、並びに単独の両化合物のブドウ糖除去に対する効力を、C57BLKS/J db/dbマウスにおける5週間の研究において試験した(n=7〜8/群)。この重度の高血糖症を有する末期(late)2型糖尿病のモデルは、抗糖尿病化合物の効力を決定するために広範に使用されている。
ビオチン、フィタン酸及び両化合物の組み合わせにより処置されたdb/dbマウスにおけるOGTTの90分目、120分目、150分目及び180分目におけるブドウ糖除去速度(コントロールに対する%ブドウ糖減少)
肝ブドウ糖代謝に関与している遺伝子の相乗的な制御に対する、化合物EGCG及びシステアミンと組み合わせられたビオチンの効果を調査した。アフィメトリックスジーンチップ(Affymetrix GeneChip)(登録商標)高密度オリゴヌクレオチドマイクロアレイアプローチを、H−4−II−Eラット肝細胞における包括的な遺伝子発現を決定するために選んだ。組み合わせ処置条件のうちの一つにおいて制御様式における相乗的な挙動を示した遺伝子をろ過し、ブドウ糖ホメオスタシスマーカー遺伝子をさらなる分析のために選択した。肝炭水化物代謝は、厳密に制御されている。二つの特異的酵素グルコキナーゼ(GK)及びグルコース−6ホスファターゼ(Glc6Pase)は、肝臓がブドウ糖ホメオスタシスにおいて決定的な役割を果たすことを可能にする。ブドウ糖の過剰産生が、ヒトにおける絶食時高血糖及び真性糖尿病の主因であるため、Glc−6−Paseによるグルコース−6−リン酸の加水分解の調整は、循環系へとブドウ糖を放出する過程における遠位の速度決定酵素工程である。肝Glc−6−Pase mRNAレベルの著しい上昇が、糖尿病動物モデルにおいて報告されている。従って、Glc−6−Paseの触媒サブユニットの発現を低下させ得る化合物又は化合物の組み合わせは、高血糖を正常化し、糖尿病状態を予防すると考えられる。EGCGは、以前に、H−4−II−E細胞におけるGlc−6−Pase mRNaレベルを低下させることが示されている。ビオチンがラット肝細胞におけるGKの発現を誘導し得ることも既知である。
H−4−II−Eラット肝細胞を、アメリカンタイプカルチャーコレクション(American Type Culture Collection)(ATCC)から入手し、37℃で、湿潤5%C02雰囲気において10%ウシ胎仔血清が補給されたメディウム(Medium)199(Invitrogen, Basel, Switzerland)において培養した。細胞をサブコンフルエンスで定期的に継代し、低い継代数で使用した。最終アッセイのため、細胞をトリプシン処理し、6穴細胞培養プレートに1×106細胞/ウェルの密度で播種し、さらに6時間、メディウム199&0.1%BSA(Invitrogen)で維持した後、化合物を適用した。EGCGはDMSOに入れて適用し;システアミンは、まず1M HClに溶解させ、次いで、刺激培地に適用し、ビオチンは培地に直接溶解させた。24時間の処理の後、全RNAを採集した。
24個の試料全てを、アフィメトリックスジーンチップ(登録商標)アレイプロトコル(Affymetrix, Santa Clara, Ca, USA)に従って調製した。簡単に説明すると、全細胞RNAを、オンカラムRNaseフリーDNaseIダイジェスト(on-column RNase-free DNase I digest)(Qiagen, Basel, Switzerland)を含むキアゲン(Qiagen)RNeasyミニキット(Mini Kit)を使用することにより抽出した。T7−(T)24プライマー(5’−GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG(dT)24−3’)を全RNA 10μgにアニーリングさせ、スーパースクリプト(Superscript)II逆転写酵素(400U)を利用して、DTT、dNTP及びl×反応緩衝液の存在下で、第一鎖cDNAを合成した。第二鎖合成は、dNTPの存在下でl×第二鎖緩衝液を含有している最終反応物にE.coli DNAポリメラーゼI(40U)、E.coliリガーゼ(10U)及びRNaseH(2U)を添加することにより実施した。最後に、T4 DNAポリメラーゼ(10U)(スーパースクリプト(Superscript)(登録商標)マイクロアレイカスタマイズドキット(Microarray Customized Kit), Invitrogen, Basel, CH)を使用して鎖を平滑末端化した。cDNAをフェノール/クロロホルム抽出により精製し、続いて、bio−16−UTP及びbio−11−CTP(Roche Molecular Biochemicals, Penzberg, Germany)を組み込むインビトロ転写を、T7 RNAポリメラーゼ(MEGASCRIPT(登録商標)T7キット(Kit), Ambion, Texas, USA)を使用して3時間実施した。RNeasy精製の後、得られたcRNA 10μgを、95℃で35分間、40mMトリス酢酸(pH8.1)、100mM酢酸カリウム及び30mM酢酸マグネシウムを使用して断片化した。アフィメトリックスジーンチップ(登録商標)発現分析技術マニュアル(Expression Analysis Technical Manual)に記載されたようにして、100mM MES緩衝液、1M NaCl、20mM EDTA、0.01%トゥイーン20、試料cRNA、断片化された細菌コントロールスパイク、ビオチン化されたオリゴ(oligo)984、ニシン精子DNA(0.5μg/μl;Invitrogen)及びアセチル化されたBSA(0.25μg/μl;Promega, Madison, WI, USA)を含有しているハイブリダイゼーションカクテルを調製した。次いで、試料を、45℃で16時間、アフィメトリックスジーンチップ(登録商標)ラット(Rat)230(SubA)へとハイブリダイズさせた。最後に、アレイを、EukGE−WS2v3プログラムを有するジーンチップ(登録商標)フルイディクス(Fluidics)400ステーション(Affymetrix)で洗浄し、抗体増幅プロトコルを使用して、ストレプトアビジンR−フィコエリトリン(SAPE)による染色を2回実施した。
生蛍光データを共焦点レーザー走査(Hewlett Packard, Palo Alto, Ca, USA)により収集し、アフィメトリックスマイクロアレイスイート(Affymetrix Microarray Suite)(MAS4.0)により分析した。データ処理はRACE−A分析ツール(Roche, Basel, Switzerland)を使用して実施した。全てのアレイを、全ての使用されたアレイ間の平均差(Average Difference)(AvgDiff)値の合計の平均値に対して規準化した。4未満の規準化AvgDiff値には、4という値を自動的に割り当てた。平均平均差値(Mean average difference values)(MeanAvgDiff)及び標準偏差(SD)をレプリケート試料から計算した。処置群は、媒体(V;0.1%DMSO);単一化合物として適用された50μM EGCG(A)、1μMビオチン(B)、50μMシステアミン(C)、並びにEGCG/ビオチン(D)及びシステアミン/ビオチン(E)の組み合わせであり;各実験をトリプリケートで実施した。包括的分析のため、p<0.05の独立t検定における有意水準と組み合わせられた最大相乗係数(synergistic factor)(SF)>+/−1を有する遺伝子をろ過した。処置群内の相対遺伝子発現は、平均平均差(MeanAvgDiff)と等しい。実験はレプリケートで行われたため、対応する平均値は、
である(ここで、媒体処置条件がVであり、単一化合物がX又はYであり、かつ多重組み合わせがMである)。相乗係数(SF)は、媒体差し引き多重遺伝子発現と、媒体差し引き相加的遺伝子発現との比率と見なされ、従って、
である。
H−4−II−Eラット肝細胞を、媒体(0.1%DMSO)、単一化合物として適用された50μM EGCG、1μMビオチン、50μMシステアミン、並びにEGCG/ビオチン及びシステアミン/ビオチンの組み合わせのいずれかにより24時間刺激した。全RNA試料をcRNAプローブへと加工し、アフィメトリックスラット230(SubA)アレイにハイブリダイズさせた。生蛍光データの計算を、アフィメトリックスMAS4.0プログラムで実施した。グルコース−6−ホスファターゼ遺伝子発現に関するMeanAvgDiff発現レベル、標準偏差(SD)及びSFの値を、RACE−Aプログラムで作製されたろ過された遺伝子のリストから取り出した。
Claims (27)
- 体重1kg当たり0.01〜約3mgの1日投薬量を対象に投与するのに十分な量のビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される少なくとも一つの付加的な成分とを含む組成物。
- ビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸及びリポ酸より選択される少なくとも一つの付加的な成分とが存在する、請求項1記載の組成物。
- パンテチンが存在する、請求項1又は2に記載の組成物。
- 体重1kg当たり1〜約50mgの1日投薬量を対象に投与するのに十分な量のパンテチンを含有している、請求項3記載の組成物。
- EGCGが存在する、請求項1〜4のいずれか1項に記載の組成物。
- 体重1kg当たり0.3〜約30mgの1日投薬量を対象に投与するのに十分な量のEGCGを含有している、請求項5記載の組成物。
- フィタン酸が存在する、請求項1〜6のいずれか1項に記載の組成物。
- 体重1kg当たり1〜約100mgの1日投薬量を対象に投与するのに十分な量のフィタン酸を含有している、請求項7記載の組成物。
- リポ酸が存在する、請求項1〜8のいずれか1項に記載の組成物。
- 体重1kg当たり0.3mg〜約30mgの1日投薬量を対象に投与するのに十分な量のリポ酸が存在する、請求項9記載の組成物。
- ポリコサノールが存在する、請求項1〜10のいずれか1項に記載の組成物。
- 体重1kg当たり0.002mg〜約1.5mgの1日投薬量を対象に投与するのに十分な量のポリコサノールが存在する、請求項11記載の組成物。
- 投薬単位剤形で存在する、請求項1〜12のいずれか1項に記載の組成物。
- 投薬単位剤形が固形投薬単位剤形である、請求項13記載の組成物。
- 投薬単位剤形が約0.35〜約200mgのビオチンを含有している、請求項14記載の組成物。
- 投薬単位剤形が液状投薬単位剤形である、請求項13記載の組成物。
- 投薬単位剤形が1ml当たり約0.35〜約200mgのビオチンを含有している、請求項16記載の組成物。
- 食品もしくは飲料、又は食品もしくは飲料用の補助組成物である、請求項1〜12のいずれか1項に記載の組成物。
- 一食分当たり約0.03〜50mgのビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される少なくとも一つの付加的な成分とを含む食品又は飲料。
- 一食分当たり約0.03〜50mgのビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸及びリポ酸より選択される少なくとも一つの付加的な成分とを含む食品又は飲料。
- 栄養補助食品組成物の製造における、ビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される少なくとも一つの付加的な成分との使用であって、体重1kg当たり0.01〜約3mgの1日投薬量を提供するのに十分な量のビオチンが使用される、使用。
- 栄養補助食品組成物の製造における、ビオチンと、パンテチン又はその代謝産物、EGCG、フィタン酸及びリポ酸より選択される少なくとも一つの付加的な成分との使用であって、体重1kg当たり0.01〜約3mgの1日投薬量を提供するのに十分な量のビオチンが使用される、使用。
- 栄養補助食品組成物が、食品もしくは飲料、又は食品もしくは飲料用の補助組成物である、請求項19〜22のいずれか1項に記載の使用。
- 栄養補助食品組成物が、1型及び2型の糖尿病の処置、並びに前糖尿病又は耐糖能異常(IGT)もしくは肥満を有する個体における2型糖尿病の予防のためのものである、請求項23記載の使用。
- 栄養補助食品組成物が、1型及び2型の糖尿病の処置、並びに前糖尿病又は耐糖能異常(IGT)もしくは肥満を有する個体における2型糖尿病の予防のための医薬組成物である、請求項24記載の使用。
- 1型及び2型の糖尿病の処置、並びに前糖尿病又は耐糖能異常(IGT)もしくは肥満を有する個体における2型糖尿病の予防のための方法であって、体重1kg当たり0.01〜約3mgの1日投薬量のビオチンを、パンテチン又はその代謝産物、EGCG、フィタン酸、リポ酸及びポリコサノールより選択される少なくとも一つの付加的な成分と共に、そのような処置を必要とする対象へ投与することを含む方法。
- 1型及び2型の糖尿病の処置、並びに前糖尿病又は耐糖能異常(IGT)もしくは肥満を有する個体における2型糖尿病の予防のための方法であって、体重1kg当たり0.01〜約3mgの1日投薬量のビオチンを、パンテチン又はその代謝産物、EGCG、フィタン酸及びリポ酸より選択される少なくとも一つの付加的な成分と共に、そのような処置を必要とする対象へ投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02018847 | 2002-08-23 | ||
EP03014625 | 2003-06-26 | ||
PCT/EP2003/009112 WO2004017766A1 (en) | 2002-08-23 | 2003-08-18 | Novel nutraceutical compositions comprising biotin |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005536543A true JP2005536543A (ja) | 2005-12-02 |
Family
ID=31947889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530180A Pending JP2005536543A (ja) | 2002-08-23 | 2003-08-18 | ビオチンを含む新規栄養補助食品組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050256178A1 (ja) |
EP (1) | EP1536698A1 (ja) |
JP (1) | JP2005536543A (ja) |
CN (1) | CN1313030C (ja) |
AU (1) | AU2003266287A1 (ja) |
WO (1) | WO2004017766A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010508823A (ja) * | 2006-11-02 | 2010-03-25 | ザ・コカ−コーラ・カンパニー | 長鎖第一級脂肪族飽和アルコールを有する高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
JP2010526784A (ja) * | 2007-05-10 | 2010-08-05 | ディーエスエム アイピー アセッツ ビー.ブイ. | 光老化防止のためのビオチンの使用 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508096A (ja) * | 2002-11-07 | 2006-03-09 | ディーエスエム アイピー アセッツ ビー.ブイ. | 没食子酸エピガロカテキンを含む新規な栄養補助組成物 |
EP1638410A1 (en) * | 2003-06-26 | 2006-03-29 | International Engineering and Trading, afgekort I.E.T. | Livestock products with an increased ppar/rxr heterodimer activator level |
CN100518733C (zh) * | 2003-09-23 | 2009-07-29 | 帝斯曼知识产权资产管理有限公司 | 用于治疗和预防糖尿病的组合物 |
ITRM20040395A1 (it) * | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
JP4849792B2 (ja) * | 2004-09-14 | 2012-01-11 | オリザ油化株式会社 | 美容用組成物 |
JP5555894B2 (ja) * | 2005-03-10 | 2014-07-23 | 日油株式会社 | 脂質代謝調整剤 |
WO2006131326A2 (en) * | 2005-06-07 | 2006-12-14 | Dsm Ip Assets B.V. | Novel use of (-)-epigallocatechin gallate |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
JP5085329B2 (ja) * | 2005-09-12 | 2012-11-28 | 協和発酵バイオ株式会社 | α−リポ酸含有組成物 |
JP2007091672A (ja) * | 2005-09-29 | 2007-04-12 | Nof Corp | アディポネクチン上昇剤 |
WO2007113007A2 (en) * | 2006-04-04 | 2007-10-11 | Dsm Ip Assets B.V. | Package containing a polyphenol and their uses |
ITMI20061024A1 (it) * | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | Pellet a base di acido lipoico |
WO2010025335A2 (en) * | 2008-08-29 | 2010-03-04 | Dr Pepper/Seven Up, Inc. | Functional consumable compositions for promoting skin health and methods for using the same |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
US8609165B1 (en) * | 2009-07-02 | 2013-12-17 | E5 Llc | Dietary supplement for optimizing glucose levels, increasing energy, and improving general health |
EP2464240A1 (en) * | 2009-08-10 | 2012-06-20 | K.D. Pharma Bexbach GMBH | Phytanic acid fractionation process, fatty acid products and use thereof |
FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
US20190134006A1 (en) * | 2010-04-06 | 2019-05-09 | Assistance Publique Hopitaux De Paris | Method of treating multiple sclerosis |
CA2910717C (en) | 2013-04-29 | 2021-01-26 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5799520A (en) * | 1980-10-27 | 1982-06-21 | Capital Medical Ass | Diabetes remedy |
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
JPH07118257A (ja) * | 1993-10-18 | 1995-05-09 | Nkk Corp | アルドースレダクターゼ阻害剤 |
JPH07233070A (ja) * | 1994-02-23 | 1995-09-05 | Taisho Pharmaceut Co Ltd | 疲労改善剤 |
JPH11507385A (ja) * | 1995-06-07 | 1999-06-29 | エルゴ サイエンス インコーポレイティド | グルコース代謝の調節法 |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6203819B1 (en) * | 1997-03-07 | 2001-03-20 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
JP2001187734A (ja) * | 1999-12-28 | 2001-07-10 | Taisho Pharmaceut Co Ltd | 2型tヘルパー細胞分化抑制剤 |
US6291533B1 (en) * | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
JP2002104964A (ja) * | 2000-08-04 | 2002-04-10 | Roche Vitamins Ag | 糖尿病処置のためのフィタン酸の使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
US6132795A (en) * | 1998-03-15 | 2000-10-17 | Protein Technologies International, Inc. | Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material |
US6261589B1 (en) * | 1999-03-02 | 2001-07-17 | Durk Pearson | Dietary supplement nutrient soft drink composition with psychoactive effect |
EP1177789A3 (en) * | 2000-08-04 | 2003-01-29 | Roche Vitamins AG | Use of phytanic acid for the treatment of diabetes |
WO2002047493A2 (en) * | 2000-12-16 | 2002-06-20 | Aventis Pharma Deutschland Gmbh | Health promoting compositions |
NL1017707C2 (nl) * | 2001-03-27 | 2002-10-01 | Jaap Meijer | Vitaminepreparaat. |
US20030004215A1 (en) * | 2001-06-15 | 2003-01-02 | Van Laere Katrien Maria Jozefa | Dietetic preparation and method for inhibiting intestinal carbohydrate absorption |
US20030068391A1 (en) * | 2001-10-04 | 2003-04-10 | Harris Dennis H. | Ingestible nerve and circulatory nutritional formulation |
-
2003
- 2003-08-18 US US10/525,348 patent/US20050256178A1/en not_active Abandoned
- 2003-08-18 CN CNB038199823A patent/CN1313030C/zh not_active Expired - Fee Related
- 2003-08-18 EP EP03792352A patent/EP1536698A1/en not_active Withdrawn
- 2003-08-18 WO PCT/EP2003/009112 patent/WO2004017766A1/en active Application Filing
- 2003-08-18 AU AU2003266287A patent/AU2003266287A1/en not_active Abandoned
- 2003-08-18 JP JP2004530180A patent/JP2005536543A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5799520A (en) * | 1980-10-27 | 1982-06-21 | Capital Medical Ass | Diabetes remedy |
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
JPH07118257A (ja) * | 1993-10-18 | 1995-05-09 | Nkk Corp | アルドースレダクターゼ阻害剤 |
JPH07233070A (ja) * | 1994-02-23 | 1995-09-05 | Taisho Pharmaceut Co Ltd | 疲労改善剤 |
JPH11507385A (ja) * | 1995-06-07 | 1999-06-29 | エルゴ サイエンス インコーポレイティド | グルコース代謝の調節法 |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
US6203819B1 (en) * | 1997-03-07 | 2001-03-20 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6291533B1 (en) * | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
JP2001187734A (ja) * | 1999-12-28 | 2001-07-10 | Taisho Pharmaceut Co Ltd | 2型tヘルパー細胞分化抑制剤 |
JP2002104964A (ja) * | 2000-08-04 | 2002-04-10 | Roche Vitamins Ag | 糖尿病処置のためのフィタン酸の使用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435587B2 (en) | 2005-11-23 | 2013-05-07 | The Coca-Cola Company | High-potency sweetener composition with long-chain primary aliphatic saturated alcohol and compositions sweetened therewith |
JP2010508823A (ja) * | 2006-11-02 | 2010-03-25 | ザ・コカ−コーラ・カンパニー | 長鎖第一級脂肪族飽和アルコールを有する高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
JP2010526784A (ja) * | 2007-05-10 | 2010-08-05 | ディーエスエム アイピー アセッツ ビー.ブイ. | 光老化防止のためのビオチンの使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2003266287A1 (en) | 2004-03-11 |
EP1536698A1 (en) | 2005-06-08 |
US20050256178A1 (en) | 2005-11-17 |
WO2004017766A1 (en) | 2004-03-04 |
CN1678203A (zh) | 2005-10-05 |
CN1313030C (zh) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005536543A (ja) | ビオチンを含む新規栄養補助食品組成物 | |
US11219590B2 (en) | Anti-aging agent and anti-aging method | |
EP1773364B1 (en) | Nutritional compositions and methods for treating or preventing osteoporosis | |
JP5566946B2 (ja) | 新規栄養補助食品組成物及びその使用 | |
EP1838172B1 (en) | Novel nutraceutical compositions | |
CN102470154B (zh) | 用于毛发护理的甜菊提取物或甜菊醇 | |
US20060165671A1 (en) | Novel nutraceutical compositions comprising epigallocatechin gallate | |
US8129337B2 (en) | Compositions comprising epigallocatechin gallate and protein hydrolysate | |
US20220031596A1 (en) | Anti-aging agent and anti-aging method | |
US20090305945A1 (en) | Novel nutraceutical compositions | |
US20200068939A1 (en) | Nutritional compositions to increase and sustain blood ketone levels | |
US20090221694A1 (en) | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone | |
KR20180075423A (ko) | 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 | |
US20100028457A1 (en) | Agent for prevention or treatment of blood glucose level elevation | |
JP2004131407A (ja) | ローヤルゼリー又はその水溶性画分を有効成分とする抗うつ性組成物 | |
EP3622951B1 (en) | Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition | |
MX2008001176A (es) | Método para tratamiento o manejo del estrés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060815 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |